In Early May 2026, cases of hantavirus were identified on the cruise ship MV Hondius, bringing the Andes strain suddenly under close scrutiny by health authorities. An alert was immediately raised, passengers were monitored, experts assessed the risk of further transmission and the scientific community once again focused on a rare but potentially serious virus.
At the same time, a critical question returned to the forefront: is there a vaccine that can protect against hantavirus? For now, the answer is no, at least not an approved and available vaccine for the Andes strain linked to these cases. However, scientists are not starting from scratch.
According to Euronews, researchers at the University of Bath in the United Kingdom were already working, before the outbreak, on a new mRNA vaccine for another hantavirus strain, Hantaan. The research team says the candidate vaccine is still in an early stage, but laboratory tests on animals have shown encouraging results.
The key question now is whether the same technology could also be applied to the Andes strain. Researchers are cautious. As Asel Sartbaeva, a chemist at the University of Bath and co‑founder of EnsiliTech, explains, it is not yet known whether the antigen developed for the Hantaan strain will also be effective against the Andes strain. This will only become clear once specific testing is carried out.
At present, there are no specific drugs or approved vaccines for the hantavirus linked to the recent cases. Health authorities note that timely medical support can improve survival chances, but the absence of targeted treatment highlights why attention is now shifting towards vaccine development.
The UK government had already assigned the research team in 2024 to develop an mRNA vaccine that could become the world’s first thermostable vaccine against the Hantaan strain. The technology used, known as ensilication, aims to make mRNA vaccines easier to transport and store, reducing the need for extremely low temperatures.
Researchers say they have already managed to move storage requirements from minus seventy degrees Celsius to standard refrigeration temperatures of two to eight degrees, with the aim of eventually enabling transport even at room temperature. If achieved, this could be crucial for faster vaccine distribution in regions where maintaining a cold chain is difficult.
Despite concerns raised by the cases, experts stress there is no reason for panic or comparison with the COVID‑19 pandemic. By 13 May, the World Health Organization had recorded eleven cases, including eight laboratory‑confirmed, two probable and one unclassified, along with three deaths, all among passengers on the cruise ship. The WHO also said there is no evidence of a wider outbreak following the disembarkation of passengers.
Sartbaeva notes that hantavirus is a rare disease that typically does not attract significant research attention. She also points out that the incident occurred in an isolated environment, limiting the potential for further spread, and emphasises that hantavirus does not transmit as easily as coronavirus.
The message is therefore twofold. On the one hand, science is not starting from zero, as research into a potential vaccine is already underway. On the other hand, the path to an available and effective vaccine for the strain linked to the MV Hondius remains open and requires further testing.
The outbreak serves as a reminder that rare viruses can suddenly move into the spotlight and that preparedness remains a key challenge for public health.
Source: ygeiamou.gr
